When Does Liraglutide's Main Patent Expire?
Liraglutide, sold as Victoza for diabetes and Saxenda for weight loss by Novo Nordisk, faces key patent expirations starting in 2023 in the US. The primary composition patent (US 6,268,343) expired June 2023, with pediatric exclusivity ending August 2023. Additional patents, like the formulation patent (US 8,114,833), extend to 2031-2033 but face challenges.[1][2]
How Will Generics Enter the Market?
Generic entry accelerates post-2023 expiry. The FDA approved the first generic liraglutide in late 2023 (from Hims & Hers and others), though manufacturing and supply delays limit immediate volume. Full competition ramps up by 2025-2026 as more ANDAs gain approval. Biosimilars are less relevant since liraglutide is synthetic, not biologic.[2][3]
Impact on Novo Nordisk
Novo loses exclusivity on a blockbuster: Victoza generated $3.9B in 2022 sales, dropping 20-30% annually post-expiry due to price erosion from generics (often 80% cheaper). This pressures margins but Novo offsets via newer drugs like semaglutide (Ozempic/Wegovy), up 50%+ in sales. R&D spend rises to defend pipeline; stock dipped 5-10% on expiry news but recovered on semaglutide strength.[1][4]
Opportunities for Generic Manufacturers
Companies like Teva, Mylan (Viatris), and Hims & Hers gain market share in the $10B+ GLP-1 diabetes/weight loss space. They capture 60-80% volume within 2 years, boosting revenues—e.g., Teva projects $500M+ annual from GLP-1 generics. Entry barriers include complex injection tech, but approvals multiply post-2023.[2][5]
Price Drops and Patient Access
US prices fell 40-60% already on first generics; expect 70-90% off list by 2026. This expands access for 10M+ diabetes patients, cutting annual costs from $10K to $1-2K. Payers save billions, shifting spend to branded upgrades like tirzepatide.[3][6]
Competitive Shifts in GLP-1 Market
Expiry intensifies rivalry: Eli Lilly's Mounjaro and Novo's semaglutide (patented to 2032+) dominate, but liraglutide generics undercut them on price. Smaller players like Pfizer eye combo products. Overall market grows 20% yearly to $100B by 2030, diluting liraglutide's slice.[4][7]
Ongoing Patent Challenges and Delays
Novo litigates secondary patents (e.g., device patents to 2034), delaying some generics via 30-month stays. Paragraph IV challenges from 15+ firms resolved mixed—5 approved, others pending. Full expiry timeline: core patents gone, but Orange Book lists 20+ until 2035.[1][2]
[1]: DrugPatentWatch.com - Liraglutide Patents
[2]: FDA Orange Book - Liraglutide
[3]: FDA Generic Approvals
[4]: Novo Nordisk Annual Report 2023
[5]: Teva Investor Presentation
[6]: IQVIA Market Data
[7]: Evaluate Pharma GLP-1 Forecast